The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commercial evolution out to 2014 and assessing trends by product, company, therapy area, geography, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.
Scope
* Comprehensive financial strategic analysis of the mAb market out to 2014
* Global sales forecasts to 2014 for marketed and Phase III mAb products
* Analysis of market trends by product, company, geography, therapy area, technology and target type
* Analysis of characteristics of key products and insight into direction of mAb technology evolution and pipeline dynamics
Highlights
The global prescription pharmaceutical market is expected to face a decline in sales over 2012 to 2013 as a result of the 'patent cliff'. The patent cliff will impact the small molecule market, in contrast, the mAb market segment will continue to record robust growth.
Over the forecast period monoclonal antibodies are predicted to enjoy double-digit growth while small molecule drugs face declining growth rates. The main barrier to sales growth for small molecules, and particularly in the US, is exposure to material generic competition, which Datamonitor believes will have no effect on mAbs out to 2014.
This attractive growth rate and sales return potential has made mAb companies a prime acquisition target in recent years, even during a period of economic uncertainty, with a number of key acquisitions made during 2008-09.
Partial Table of Contents:
-- Full ToC is available at http://www.fastmr.com/
ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this Sector Report
PharmaVitae Explorer database
Chapter structure
Executive summary
mAb technology overview
Market analysis
Pipeline analysis
Key products
Data sourcing
Sales data
Chapter 2 Executive summary
Key findings
Total prescription pharmaceutical market outlook
Monoclonal antibody market outlook
Introduction to the PharmaVitae company universe
The prescription pharmaceutical market to 2014
Prescription pharmaceutical market performance, 2008-14
Introduction to molecule type analysis
Small molecules
Therapeutic proteins
Monoclonal antibodies
Vaccines
Industry consequences of molecule type
Prescription pharmaceutical sales by molecule type, 2008-14
The monoclonal antibody market will deliver the biggest portion of sales growth across the entire pharmaceutical industry, at the fastest rate
The mAb market is forecast to increase at a double-digit growth rate
The monoclonal antibody market will deliver much-needed sales growth in order to offset US-centered small molecule sales collapse
Geographic sales growth: the US and 5EU lead the way
A raft of new mAbs expected to make it onto the market over 2008-14...
...but still only a few mAbs command the highest revenues
Introduction to the 'Big 5'
'Big 5' dominance will remain, although their share will decline
Product analysis (size)
Product analysis (growth)
Company analysis
Big Pharma's hold on the mAb market
Recent M&A deals underline Pharma's 'bankable view' of mAbs
The mAb landscape: innovation driven by collaboration and M&A
Long term opportunities and threats
Long term threat of biosimilar mAbs?
The US offers the 'biggest biosimilar prize'
Price of mAb therapies a major resistor to growth, however, the collapse of the US branded small molecule market could 'free-up' payer resource to expand mAb purchasing
Drive for personalized medicine: the role of companion diagnostics, an opportunity for diagnostic and mAb players
Table of Contents
Table of figures
Chapter 3 MAb Technology Overview
Key findings
Introduction
The immune system
B lymphocytes and antibodies
Antibody structure
Hybridoma technique - the production of mAbs
Monoclonal antibodies as therapeutic agents
Targets
Target selection - the importance of an accessible epitope
Production of mAbs
Transgenic mice
Phage display
Future focus
Mode of action
mAb-focused oncology
The effect of the effector region
Blockade
MAbs as a delivery vehicle
Evolution of mAbs
For more information or to purchase this report, go to http://www.fastmr.com/
About Datamonitor
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
